LIGAND PHARMACEUTICALS INCORPORATED Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $390.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-11-14.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2016-11-14
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2015-12-31 was $0.00, a 100.00% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2015-06-30 was $93.00K, a 73.80% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2015-03-31 was $297.00K, a 7.61% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2015 was $390.00K, a 68.62% decline from fiscal 2014.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2014 was $1.24M, a 62.45% decline from fiscal 2013.
- LIGAND PHARMACEUTICALS INCORPORATED fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2013 was $3.31M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $93.00K derived: sum of 3 quarters · filed 2016-11-14 | $390.00K 10-K · filed 2016-11-14 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $93.00K derived: sum of 2 quarters · filed 2015-11-09 | $390.00K 10-Q · filed 2015-11-09 | $631.00K derived: sum of 4 quarters · filed 2015-11-09 | |
| 2015-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $390.00K 10-Q · filed 2015-08-05 | $631.00K derived: sum of 3 quarters · filed 2015-08-05 | $1.00M derived: sum of 4 quarters · filed 2015-08-05 | |
| 2015-03-31 | $297.00K 10-Q · filed 2015-05-11 | $538.00K derived: sum of 2 quarters · filed 2015-05-11 | $909.00K derived: sum of 3 quarters · filed 2015-05-11 | $1.26M derived: sum of 4 quarters · filed 2015-05-11 | |
| 2014-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-23 | $612.00K derived: sum of 2 quarters · filed 2015-02-23 | $967.00K derived: sum of 3 quarters · filed 2015-02-23 | $1.24M 10-K · filed 2015-02-23 | $3.31M 10-K · filed 2014-12-01 |
| 2014-09-30 | $371.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-31 | $726.00K derived: sum of 2 quarters · filed 2014-10-31 | $1.00M 10-Q · filed 2014-10-31 | $1.86M derived: sum of 4 quarters · filed 2014-12-12 | |
| 2014-06-30 | $355.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $631.00K 10-Q · filed 2014-08-05 | $1.49M derived: sum of 3 quarters · filed 2014-12-12 | $6.15M derived: sum of 4 quarters · filed 2014-12-12 | |
| 2014-03-31 | $276.00K 10-Q · filed 2014-05-07 | $1.14M derived: sum of 2 quarters · filed 2014-12-12 | $5.79M derived: sum of 3 quarters · filed 2014-12-12 | $6.09M derived: sum of 4 quarters · filed 2014-12-12 | |
| 2013-12-31 | $860.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2014-12-12 | $5.52M derived: sum of 2 quarters · filed 2014-12-12 | $5.82M derived: sum of 3 quarters · filed 2014-12-12 | $3.31M 10-K/A · filed 2014-12-12 | |
| 2013-09-30 | $4.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $4.96M derived: sum of 2 quarters · filed 2013-11-08 | $2.45M 10-Q · filed 2013-11-08 | ||
| 2013-06-30 | $302.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | -$2.21M 10-Q · filed 2013-08-01 | |||
| 2013-03-31 | -$2.51M 10-Q · filed 2013-05-08 |